MedTrace Logo

Radiofrequency Ablation of Symptomatic Frequent Ventricular Premature Complexes in Pediatric Population

NCT02772354 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2016-09-09

No results posted yet for this study

Summary

To evaluate the effectiveness and safety of catheter ablation of frequent symptomatic PVCs in the pediatric population as first-line therapy compared with antiarrhythmic drugs.

Conditions

  • Ventricular Arrhythmia

Interventions

PROCEDURE

Radiofrequency catheter ablation

Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool

DRUG

Metoprolol

Antiarrhythmic therapy of premature ventricular complexes Metoprolol 12-50 mg

DRUG

Verapamil

Verapamil 20-240 mg

DEVICE

NAVI-STAR® RMT ThermoCool

Sponsors & Collaborators

  • Meshalkin Research Institute of Pathology of Circulation

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-09-30
Completion
2018-04-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02772354 on ClinicalTrials.gov